Key result
A targeted next-generation sequencing panel identified deleterious variants associated with autosomal dominant cardiac diseases in 33.3% of patients with familial aggregation of pacemaker implantation.
Observational (n=112)
A targeted 246-gene next-generation sequencing panel identified potentially pathogenic variants in 33.3% of patients with familial aggregation of pacemaker implantation, suggesting a significant genetic component in this population.
Answers are grounded in this paper and cite their sources.
May support NGS panels for variant detection in faPPM; leaves open routine clinical use pending validation.
BACKGROUND: The etiology of conduction disturbances necessitating permanent pacemaker (PPM) implantation is often unknown, although familial aggregation of PPM (faPPM) suggests a possible genetic basis. We developed a pan-cardiovascular next generation sequencing (NGS) panel to genetically characterize a selected cohort of faPPM. MATERIALS AND METHODS: We designed and validated a custom NGS panel targeting the coding and splicing regions of 246 genes with involvement in cardiac pathogenicity. We enrolled 112 PPM patients and selected nine (8%) with faPPM to be analyzed by NGS. RESULTS: Our NGS panel covers 95% of the intended target with an average of 229x read depth at a minimum of 15-fold depth, reaching a SNP true positive rate of 98%. The faPPM patients presented with isolated cardiac conduction disease (ICCD) or sick sinus syndrome (SSS) without overt structural heart disease or identifiable secondary etiology. Three patients (33.3%) had heterozygous deleterious variants previously reported in autosomal dominant cardiac diseases including CCD: LDB3 (p.D117N) and TRPM4 (p.G844D) variants in patient 4; TRPM4 (p.G844D) and ABCC9 (p.V734I) variants in patient 6; and SCN5A (p.T220I) and APOB (p.R3527Q) variants in patient 7. CONCLUSION: FaPPM occurred in 8% of our PPM clinic population. The employment of massive parallel sequencing for a large selected panel of cardiovascular genes identified a high percentage (33.3%) of the faPPM patients with deleterious variants previously reported in autosomal dominant cardiac diseases, suggesting that genetic variants may play a role in faPPM.
No takes yet. Share an insight, caveat, or question.
Celestino-Soper et al. (2015) conducted an observational in Familial aggregation of pacemaker implantation (n=112). Next-generation sequencing of cardiovascular genes was evaluated on Identification of deleterious genetic variants. A targeted next-generation sequencing panel identified deleterious variants associated with autosomal dominant cardiac diseases in 33.3% of patients with familial aggregation of pacemaker implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: